Lactobacillus brevis capable of digesting oligosaccharides and producing high-chain fatty acids and application thereof

Lactobacillus breris HB-01 obtained by screening solved the intestinal gas problem caused by indigestion of oligosaccharides in the prior art, and achieved the production of high-yield γ-aminobutyric acid and short-chain fatty acids and oligosaccharide digestion. , has significant economic value and application potential.

CN115948284BActive Publication Date: 2024-11-12HEFEI MICROHE HEXAGON BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211474984.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-23
Publication Date
2024-11-12
Estimated Expiration
2042-11-23

AI Technical Summary

Technical Problem

Latbacter brevia, which has digestible oligosaccharides with high yield of short-chain fatty acids, cannot effectively solve the problems of intestinal gas and diarrhea caused by indigestion in the gastrointestinal tract.

Method used

Screening resulted in a Lactobacillus breris HB-01. This strain is not only able to produce high yields of gamma-aminobutyric acid and short-chain fatty acids, but also digest oligosaccharides such as raffinose and sedrosose, with a broad range of Application prospects.

Benefits of technology

Lactobacillus brevis is acid-resistant and bile salt-resistant, can efficiently produce γ-aminobutyric acid and short-chain fatty acids, can effectively digest oligosaccharides, improve intestinal health, and reduce intestinal gas risks. It has significant economic value and application potential .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115948284B_ABST
    Figure CN115948284B_ABST
Patent Text Reader

Abstract

The present invention discloses a Lactobacillus breris that can digest oligosaccharides and a high-yield short-chain fatty acid and its application, and relates to the field of microbial technology. The Lactobacillus breris of the present invention is named Lactobacillus breris (Lactobacillus breris) HB-01, which has been deposited in the China Center for Type Culture Collection on May 20, 2022, with an address of Wuhan University, Wuhan, China, and a deposit number of CCTCC NO: M2022686. The Lactobacillus breris of the present invention has acid and bile resistance, and has the ability to produce high γ-aminobutyric acid and short-chain fatty acids such as acetic acid, propionic acid, and butyric acid after fermentation; the Lactobacillus breris of the present invention has the property of utilizing oligosaccharides such as stachyose and raffinose.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, and in particular to a Lactobacillus brevis capable of digesting oligosaccharides and producing high-chain fatty acids and application thereof. Background Art

[0002] Lactobacillus brevis is an important species of lactic acid bacteria, and lactic acid bacteria are generally recognized as safe (GRAS) food-grade microorganisms and are now widely used in various industries. Studies have shown that Lactobacillus brevis has multiple functional characteristics and has been gradually applied in the food, health care, environmental protection and other industries and has achieved significant benefits. In the environmental protection industry, Wu Wei et al. found that the ability of Lactobacillus brevis A1.558 bacteria and metabolites to remove nitrite has a significant effect in aquaculture water bodies and has great potential as an environmental remediation product for aquaculture water bodies. In the health care industry, the Lactobacillus brevis isolated and screened by Watanabe et al. has the effect of effectively reducing cholesterol in vitro; Li et al. isolated and screened Lactobacillus brevis with high γ-aminobutyric acid production capacity. In the food industry, Lactobacillus brevis can be used as a fermentation strain to ferment various products, such as a direct-injection starter to ferment kimchi. Deng et al. isolated and screened a strain of Lactobacillus brevis from kefir grains that can survive high selenium concentrations and reduce sodium selenite to selenium, thereby preparing a functional dairy element-enriched fermented milk.

[0003] γ-Aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the brain of mammals and a non-protein amino acid. The precursor of GABA is glutamate. The enzymes necessary for the synthesis of GABA include glutamate decarboxylase (gadB) and glutamate / GABA antiporter (gadC). GABA participates in the regulation of multiple processes in the human body and has antidepressant and sedative effects. Intestinal bacteria that produce active neurochemicals are considered by relevant scholars to be potential psychoactive biological agents, and the main producer of GABA in bacteria is lactic acid bacteria. Short-chain fatty acids are organic fatty acids with 1 to 6 carbon atoms, mainly acetic acid, propionic acid and butyric acid, and are considered to be beneficial to human intestinal health. Short-chain fatty acids produced by probiotics in the intestine can significantly improve the body's intestinal performance, maintain the metabolic homeostasis of colon cells, protect colon cells from external damage, etc., while improving the body's health. In addition, short-chain fatty acids also have an intervention effect on mental illnesses such as Parkinson's syndrome. Raffinose and stachyose are oligosaccharides contained in some bean seeds. They are the main oligosaccharides that cause gastrointestinal bloating in animals and are considered to be the bloating factor of soybeans. The content of raffinose in soybeans is about 1%, and the content of stachyose in soybeans is about 4%. Raffinose and stachyose ingested by the human body are not easily digested and decomposed in the gastrointestinal tract. The digestive enzymes in the upper part of the human gastrointestinal tract cannot digest raffinose and stachyose. When raffinose and stachyose pass through the colon, aerobic bacteria in the intestine will decompose them to produce carbon dioxide, methane, hydrogen and other gases, thereby causing symptoms such as intestinal bloating, flatulence, and diarrhea.

[0004] There is no report on Lactobacillus brevis that can digest oligosaccharides and produce high-chain fatty acids. Summary of the invention

[0005] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a Lactobacillus brevis that can digest oligosaccharides and produce high-chain fatty acids and its application. The Lactobacillus brevis of the present invention has the ability to produce high-gamma-aminobutyric acid and short-chain fatty acids and can digest oligosaccharides.

[0006] To achieve the above purpose, the technical solution adopted by the present invention is: a Lactobacillus breris, named Lactobacillus breris HB-01, has been deposited in the China Center for Type Culture Collection on May 20, 2022, with the address of Wuhan University, Wuhan, China, and the deposit number is CCTCC NO: M2022686. The Lactobacillus breris screened by the present invention has the ability to produce high γ-aminobutyric acid and short-chain fatty acids, and can digest oligosaccharides, and has broad application prospects and economic value.

[0007] As a preferred embodiment of the Lactobacillus brevis of the present invention, the sequence of the Lactobacillus brevis is shown as SEQ ID NO.1.

[0008] As a preferred embodiment of the Lactobacillus brevis of the present invention, the Lactobacillus brevis is isolated from Hefei kimchi. The Lactobacillus brevis of the present invention is isolated from Hefei kimchi, and the strain HB-01 is determined to be Lactobacillus brevis through catalase test, indole test, methyl red test, VP test, hydrogen sulfide production test, bile salt hydrolase activity test, hemolysis reaction test, sugar biochemical test and 16S rDNA identification.

[0009] The present invention also provides the use of the Lactobacillus brevis in preparing short-chain fatty acids or gamma-aminobutyric acid.

[0010] The inventors of the present application have found through experiments that the Lactobacillus brevis of the present invention can produce high levels of γ-aminobutyric acid, and has anti-depressant, hypnotic, etc. The Lactobacillus brevis of the present invention can also produce short-chain fatty acids.

[0011] As a preferred embodiment of the application of the present invention, the short-chain fatty acid is at least one of acetic acid, propionic acid or butyric acid.

[0012] The invention also provides the use of the Lactobacillus brevis in in vitro digestion of oligosaccharides.

[0013] Raffinose and stachyose are oligosaccharides contained in some legume seeds, which are the main oligosaccharides that cause gastrointestinal bloating in animals and are considered to be soybean bloating factors. The inventors of the present application have found through experiments that the Lactobacillus brevis of the present invention has the property of utilizing stachyose and raffinose.

[0014] As a preferred embodiment of the application of the present invention, the oligosaccharide is at least one of raffinose or stachyose.

[0015] The present invention also provides a method for preparing a fermentation liquid containing short-chain fatty acids or gamma-aminobutyric acid by using the Lactobacillus brevis, wherein the Lactobacillus brevis is activated and inoculated into a short-chain fatty acid culture medium or a gamma-aminobutyric acid culture medium, and the fermentation liquid is obtained by culturing and fermenting.

[0016] As a preferred embodiment of the method of the present invention, the short-chain fatty acid culture medium comprises the following components in mass percentage: 0.1% Tween-80, 3.0% glucose, 0.5% sodium acetate trihydrate, 0.2% triammonium citrate, 0.2% dipotassium hydrogen phosphate heptahydrate, 1% peptone, 0.5% beef extract powder, 0.4% yeast powder, 0.02% magnesium sulfate heptahydrate, and 0.005% manganese sulfate tetrahydrate.

[0017] As a preferred embodiment of the method of the present invention, the γ-aminobutyric acid culture medium comprises the following components in mass percentage: 1% sodium glutamate, 0.1% Tween-80, 2.0% glucose, 0.5% sodium acetate trihydrate, 0.2% triammonium citrate, 0.2% dipotassium hydrogen phosphate heptahydrate, 1% peptone, 0.5% beef extract powder, 0.4% yeast powder, 0.02% magnesium sulfate heptahydrate, and 0.005% manganese sulfate tetrahydrate.

[0018] Beneficial effects of the present invention: The present invention provides a new Lactobacillus brevis, which has the properties of acid and bile salt resistance, and has the ability to produce high-yield γ-aminobutyric acid and short-chain fatty acids such as acetic acid, propionic acid, butyric acid, etc. after fermentation; the Lactobacillus brevis of the present invention has the property of utilizing oligosaccharides such as stachyose and raffinose. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is the colony morphology of Lactobacillus brevis HB-01.

[0020] Figure 2 This is the Gram staining image of Lactobacillus brevis HB-01.

[0021] Figure 3 This is the result of the indole test of Lactobacillus brevis HB-01.

[0022] Figure 4 This is the result of the methyl red test of Lactobacillus brevis HB-01.

[0023] Figure 5 This is a graph showing the test results of Lactobacillus brevis HB-01V-P.

[0024] Figure 6 This is a test diagram of hydrogen sulfide production by Lactobacillus brevis HB-01.

[0025] Figure 7 This is a graph showing the results of a bile salt hydrolase activity test of Lactobacillus brevis HB-01.

[0026] Figure 8 This is a graph showing the results of the hemolytic reaction test of Lactobacillus brevis HB-01.

[0027] Fig. 9 This is the result of the experiment on sugar biochemical utilization of stachyose by Lactobacillus brevis HB-01.

[0028] Fig.10 This is the result of the experiment on biochemical utilization of raffinose by Lactobacillus brevis HB-01.

[0029] Fig.11 This is the development and color development diagram in the paper chromatography quantitative experiment of Lactobacillus brevis HB-01.

[0030] Fig.12 This is a standard curve of GABA.

[0031] Fig.13 This is the curve of GABA production by Lactobacillus brevis HB-01 fermentation.

[0032] Fig.14 This is a graph showing the experimental results of producing short-chain fatty acids by fermentation of Lactobacillus brevis HB-01.

[0033] Fig.15 This is the acid resistance test result of Lactobacillus brevis HB-01.

[0034] Fig.16 This is a graph showing the bile salt resistance test results of Lactobacillus brevis HB-01. DETAILED DESCRIPTION

[0035] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention.

[0036] Example 1 Preservation information of Lactobacillus brevis

[0037] The present invention provides a Lactobacillus breris, which is named Lactobacillus breris HB-01, and has been deposited in the China Center for Type Culture Collection on May 20, 2022, with the address being Wuhan University, Wuhan, China, and the deposit number being CCTCC NO: M2022686.

[0038] Example 2 Screening and identification of Lactobacillus brevis

[0039] 2.1 Use Hefei kimchi as sample for strain screening.

[0040] Prepare MRS medium, take samples in MRS medium, and culture at 37℃ for 18-24h. Take 200μL of the above bacterial solution and spread it on MRS solid medium plate, and culture at 37℃ for 48h. Pick colonies with good growth conditions, inoculate them on MRS solid medium plate by streak method, culture at 37℃ for 48h, and observe the morphological characteristics of each colony.

[0041] 2.2 Preliminary identification of lactic acid bacteria

[0042] Gram staining and catalase (catalase) test were used to preliminarily identify whether the strain screened in 2.1 was lactic acid bacteria. The catalase test was as follows: 10% hydrogen peroxide solution was dripped onto the bacterial lawn, and bubbles were generated if positive, and no bubbles were generated if negative.

[0043] 2.3 Screening of strains with negative indole test results

[0044] Take the strain preservation glycerol tube and activate it. Perform three activations (once on MRS plate and twice in MRS liquid), wash it twice with sterile saline, and then resuspend the bacterial solution to 10% with sterile water in a 2# turbidity tube. 8 CFU / mL; inoculate 1% (v / v) in a 5ml peptone water medium test tube and culture at 37℃ for 48h. After 48h, gently shake the bacterial solution, add 0.3ml indigo matrix reagent, and gently shake the test tube. Observe the color change of the reagent. If the reagent is dark red, it is positive, and if it does not change color, it is negative.

[0045] 2.4 Screening of strains with negative methyl red test results

[0046] Take the strain preservation glycerol tube and activate it. Perform three activations (once on MRS plate and twice in MRS liquid), wash it twice with sterile saline, and then resuspend the bacterial solution to 10% with sterile water in a 2# turbidity tube. 8 CFU / mL; inoculate 1% (v / v) in a 5ml peptone water medium test tube, culture at 37℃ for 48h, add 50μl methyl red reagent along the tube wall after 48h to observe the color change. If the color changes to red, it is positive, and if it does not change color, it is negative.

[0047] 2.5 Screening of strains with negative VP test results

[0048] Take the strain preservation glycerol tube and activate it. Perform three activations (once on MRS plate and twice in MRS liquid), wash it twice with sterile saline, and then resuspend the bacterial solution to 10% with sterile water in a 2# turbidity tube. 8 CFU / mL; inoculate in a 5ml peptone water medium test tube at 1% (v / v), and culture at 37℃ for 48h. After 48h, take 1ml of culture medium, add 0.6ml reagent A (0.5g α-naphthol dissolved in 10ml 95% ethanol) and 0.2ml reagent B (8g KOH and 0.06g creatine dissolved in 20ml ultrapure water), mix in an uncovered test tube, and shake for 30min. If red is displayed, it is a positive reaction.

[0049] 2.6 Screening of strains with negative results in hydrogen sulfide production test

[0050] Take the strain preservation glycerol tube and activate it. Perform three activations (once on MRS plate and twice in MRS liquid), wash it twice with sterile saline, and then resuspend the bacterial solution to 10% with sterile water in a 2# turbidity tube. 8 CFU / mL; use the handle of a long inoculation spatula to dip the prepared bacterial solution and puncture the culture medium, and culture at 37℃ / 1-6d; observe for 6 days, if the culture medium turns black, it is positive.

[0051] 2.7 Screening of strains with negative results in bile salt hydrolase activity test

[0052] Take the strain preservation glycerol tube and activate it. Perform three activations (once on MRS plate and twice in MRS liquid), wash it twice with sterile saline, and then resuspend the bacterial solution to 10% with sterile water in a 2# turbidity tube. 8 CFU / mL; take 50μl and spread it on 0.5% TDCA-MRS agar medium, culture it upside down at 37℃ for 1-5d, observe it for 5d, and the presence of deoxycholic acid precipitate in the agar medium below and around the colony is considered to contain bile salt hydrolase activity.

[0053] 2.8 Screening of strains with negative hemolytic test results

[0054] Take the strain preservation glycerol tube and activate it. Perform three activations (once on MRS plate and twice in MRS liquid), wash it twice with sterile saline, and then resuspend the bacterial solution to 10% with sterile water in a 2# turbidity tube. 8 CFU / mL; use an inoculation loop to dip an appropriate amount of bacterial solution and streak it on the blood plate culture medium, invert and culture at 37℃ for 72h, and observe after 72h. If there is no hemolytic zone around the colony, it is considered to have no effect on hemolysis or no hemolysis, that is, γ-hemolysis.

[0055] 2.9 16S rDNA sequence analysis and identification

[0056] The strains isolated from the above screening were commercially sequenced by Universal Biotechnology (Anhui) using universal primers for lactic acid bacteria.

[0057] The experimental results are shown in the figure. Figure 1 It can be seen that the colony of this strain is round, milky white, smooth, convex, with neat edges and opaque. Figure 2 It can be seen that the Gram staining result of this strain showed purple, which is a Gram-positive bacillus; the catalase test result showed that no bubbles were produced; in summary, this strain was preliminarily identified as lactic acid bacteria. Figure 3 It can be seen that the test tube solution of Lactobacillus brevis HB-01 and the blank control group did not change color, indicating that the indole test result of this strain was negative. Figure 4 It can be seen that the test tube solution of the test tube with Lactobacillus brevis HB-01 and the blank control group did not change color, indicating that the methyl red test result of this strain was negative. Figure 5 It can be seen that the test tube solution of the test tube with Lactobacillus brevis HB-01 and the blank control group did not change color, indicating that the VP test result of this strain was negative. Figure 6 It can be seen that the test tubes with Lactobacillus brevis HB-01 and the blank control group did not turn black, indicating that the strain does not produce hydrogen sulfide. Figure 7 It can be seen that this strain does not have bile salt hydrolase activity. Figure 8It can be seen that the strain is a γ-hemolytic strain. After 16S rDNA identification, the nucleotide sequence of the strain is shown in SEQ ID NO. 1. Based on the results of morphological, physiological and biochemical and molecular biological tests, the strain was identified as Lactobacillus brevis.

[0058] Example 3 Determination of oligosaccharide digestion characteristics of Lactobacillus brevis HB-01

[0059] 3.1 Preparation of sugar biochemical culture medium: Mix 5 g / L sugar (stachyose or raffinose), 0.5 g / L Tween-80, 5 g / L peptone, 5 g / L yeast powder, 5 g / L beef extract powder, 2 g / L agar, and 1.4 ml / L 1.6% bromocresol purple ethanol solution, and dispense into 10*100 mm test tubes. Place an inverted 6*30 mm Dulbecco tubule in the test tube.

[0060] 3.2 Sugar biochemical test: Lactobacillus brevis HB-01 was activated three times (once on MRS plate and twice in MRS liquid), then washed twice with sterile saline and resuspended in sterile water to 10 9 CFU / ml; inoculate the resuspended bacterial solution at 1% (v / v) at the bottom of the above sugar biochemical culture medium, culture at 37℃ / 48h, and observe the color change after 48h.

[0061] The experimental results are shown in Table 1 and Figures 9-10 As shown. Fig. 9 and Fig.10 It can be seen that the solution in the test tube added with Lactobacillus brevis HB-01 changed from purple to yellow, while the test tube solution of the blank control group remained purple, which indicates that Lactobacillus brevis HB-01 has the function of digesting and utilizing stachyose or raffinose.

[0062] Table 1

[0063]

[0064]

[0065] Example 4 Determination of oligosaccharide digestion characteristics of soy milk co-fermented by Lactobacillus brevis HB-01 and commercial bacterial agents

[0066] 4.1 Co-fermentation of Lactobacillus brevis HB-01 with commercial bacterial agents Fermentation of soy milk to digest oligosaccharides: 20.45% (w / w) Dragon King brand soy milk powder, 0.5% (w / w) edible glucose and 79.05% (w / w) purified water were mixed, and the mixture was placed in a 95°C water bath for 20 min, and then cooled to 37-40°C. Lactobacillus brevis HB-01 was activated three times (once on MRS plate and twice on MRS liquid), and then washed twice with sterile saline, and resuspended in sterile water to 10 8CFU / ml. CHR HANSEN-YoFlexMild 1.0 direct-injection bacteria (including Lactobacillus bulgaricus and Streptococcus thermophilus) of Denmark was added to the cooled soy milk at 64 mg / L. The experimental group added HB-01 resuspended bacterial solution at 1% (v / v) to CHR HANSEN-YoFlexMild 1.0 direct-injection bacteria (including Lactobacillus bulgaricus and Streptococcus thermophilus), mixed thoroughly, and fermented at 37°C / 16h. The contents of raffinose and stachyose in soy milk, commercial bacterial agent fermented soy milk and three-bacteria fermented soy milk were determined respectively.

[0067] 4.2 Quantitative detection test of stachyose and raffinose: ion chromatography, Carbo Pac PA20 (3mm*150mm); pulsed amperometric detector (gold electrode); sugar standard four-potential waveform detection; injection volume 20μl; flow rate 1.0ml / min; column temperature 30℃; mobile phase A is deionized water, phase B is 10g / L sodium hydroxide solution, and phase C is 41g / L sodium acetate solution; elution mode is three-phase gradient elution, and the elution program is shown in Table 2.

[0068] Table 2

[0069] Time / min A / % B / % C / % 0 60 40 0 15 60 40 0 16 48 45 7 40 3 45 52 45 3 45 52 50 60 40 0

[0070] The experimental results are shown in Table 3. As can be seen from Table 3, the co-fermentation of soy milk with commercial bacteria and HB-01 can better reduce the content of stachyose and raffinose in soy milk, which shows that the co-fermentation of Lactobacillus brevis HB-01 and commercial bacteria has a better effect of utilizing stachyose and raffinose than the fermentation of soy milk with commercial bacteria alone.

[0071] Table 3

[0072] Content mg / kg Soy milk Commercial bacterial fermented soy milk Three bacteria fermented soy milk Stachyose 11.3 10.5 5.8 Raffinose 3.3 2.8 1.7

[0073] Example 5 Determination of high-yield γ-aminobutyric acid characteristics of Lactobacillus brevis HB-01

[0074] 5.1 Preparation of culture medium: Mix 1% sodium glutamate, 0.1% Tween-80, 2.0% glucose, 0.5% sodium acetate trihydrate, 0.2% triammonium citrate, 0.2% dipotassium hydrogen phosphate heptahydrate, 1% peptone, 0.5% beef extract powder, 0.4% yeast powder, 0.02% magnesium sulfate heptahydrate, and 0.005% manganese sulfate tetrahydrate, sterilize at 121°C for 20 min, and set aside.

[0075] 5.2 Preparation of fermentation broth: Activate the strain preservation glycerol tube, activate three times (once on MRS plate, twice in MRS liquid), take an appropriate amount of bacterial liquid in 8 ml of 1% above medium at 1% (v / v), culture at 37°C for 48 hours to obtain fermentation broth, centrifuge the fermentation broth at 18°C, 6000 rpm for 10 minutes, take the supernatant and filter it into a 2 ml ep tube using a 0.22 μm filter membrane, sample every 8 hours until 48 hours, and measure pH and OD600 while sampling. Repeat the experiment three times.

[0076] 5.3 Quantitative analysis of GABA concentration in fermentation broth by paper chromatography: (1) Spotting: The sample was spotted on Xinhua No. 1 filter paper (specifications: 30 cm*25 cm, chromatographic spot distance 2.5 cm from bottom line, chromatographic spot interval 2.0 cm) using a 10 μl microsyringe. The spotting volume was 5 μl (spotting in batches, 2.5 μl each time, and continued spotting after drying, for a total of 2 times). At the same time, a standard solution (1 g / L GABA + 10 g / L sodium glutamate) was used as a control. After the sample was spotted and the spot was dry, the filter paper was sewn into a cylindrical shape using absorbent cotton thread. The developing agent (n-butanol: glacial acetic acid: ultrapure water: hydrated ninhydrin = 500 ml: 300 ml: 200 ml: 12 g) was placed in a beaker and placed in a chromatography cylinder with the spotted filter paper. The mixture was equilibrated at room temperature for 30 min. (2) Development and color development: After 30 minutes of equilibrium, place the end of the filter paper with the sample in the developer, with the liquid level not exceeding the chromatography point, and develop at room temperature for 5-6 hours. When the solvent front reaches 20 cm from the filter paper, take it out and cut the suture cotton thread; heat in an oven at 90°C for 1 hour to develop color. (3) Determination of GABA standard curve (spectrophotometry): Prepare 0.5g / L, 1.0g / L, 2.0g / L, 3.0g / L, 4.0g / L, and 5.0g / L GABA standard solutions respectively, and perform paper chromatography according to methods 4.2.1 and 4.2.2. The spot that coincides with the position of the GABA standard was cut out, and the sample was eluted in 5.0 ml of eluent (1% CuSO4·5H2O: 75% ethanol (v / v) = 1:19) at 50 rpm / 40°C for 60 min. The blank paper eluent was used as the zero calibration, and the absorbance of the standard solution eluent at 520 nm was measured. The linear regression equation (Y = 0.1659*X + 0.0788, R2 = 0.9905) was obtained based on the relationship between the absorbance value and the GABA concentration. (4) Determination of GABA content in fermentation broth: The spot that coincides with the position of the GABA standard was cut out, and the sample was eluted in 5.0 ml of eluent (1% CuSO4·5H2O: 75% ethanol (v / v) = 1:19) at 50 rpm / 40°C for 60 min. The blank paper eluent was used as the zero calibration, and the absorbance of the sample eluent at 520 nm was measured. Calculate the GABA concentration in the fermentation broth according to the GABA standard curve obtained in 4.2.3.

[0077] The experimental results are as follows Figures 11 to 13 As shown. Fig.13 It can be seen that Lactobacillus brevis HB-01 has a high ability to produce GABA.

[0078] Example 6 Determination of short-chain fatty acid production characteristics of Lactobacillus brevis HB-01

[0079] 6.1 Preparation of culture medium: Mix 0.1% Tween-80, 3.0% glucose, 0.5% sodium acetate trihydrate, 0.2% triammonium citrate, 0.2% dipotassium hydrogen phosphate heptahydrate, 1% peptone, 0.5% beef extract powder, 0.4% yeast powder, 0.02% magnesium sulfate heptahydrate, and 0.005% manganese sulfate tetrahydrate, sterilize at 121°C for 20 min, and set aside.

[0080] 6.2 Preparation of fermentation broth: Activate the strain preserved in a glycerol tube. After three activations (once on an MRS plate and twice in MRS liquid), add an appropriate amount of bacterial solution to 8 ml of the above culture medium at 1% (v / v). Incubate at 37°C for 48 h to obtain fermentation broth. Centrifuge the fermentation broth at 18°C, 6000 rpm for 10 min. Take the supernatant and filter it into a 2 ml ep tube using a 0.22 μm PES membrane filter.

[0081] 6.3 HPLC quantitative determination of short-chain fatty acid concentration in fermentation broth:

[0082] Chromatographic conditions: HPX-87H Column (300*7.8mm); mobile phase: 0.05% H2SO4 (w / v); differential detector; injection volume: 10 μl; flow rate: 0.5 ml / min; column temperature: 60°C; elution mode: isocratic elution.

[0083] Prepare 0.50 g / L, 0.75 g / L, 1.00 g / L, 1.25 g / L and 1.50 g / L acetic acid, sodium propionate and butyric acid standard solutions respectively, perform HPLC determination according to the above chromatographic conditions, and obtain a linear regression equation based on the peak area and the concentration of the standard solution.

[0084] A sample of HB-01 short-chain fatty acid fermentation broth was taken for HPLC determination, and the concentration of short-chain fatty acids (acetic acid, propionic acid, butyric acid) in the fermentation broth was calculated according to the above regression equation.

[0085] The experimental results are as follows Fig.14 As shown by Fig.14 It can be seen that Lactobacillus brevis HB-01 has the ability to produce short-chain fatty acids (acetic acid, propionic acid, butyric acid).

[0086] Example 7 Determination of acid and bile resistance properties of Lactobacillus brevis HB-01

[0087] 7.1 Determination of acid resistance of Lactobacillus brevis HB-01: Activate the strain preservation glycerol tube, wash once with sterile saline after three activations (once on MRS plate, twice in MRS liquid), and resuspend to 1 / 3 of the original volume with sterile water; then inoculate 1% (v / v) in 8ml MRS medium with different pH (2.23, 2.70, 3.19, 3.64), and culture at 37°C / 100rpm. Samples were taken at 0, 1, 2, 3, and 4h respectively, and counted by dilution plate method, and counted after inverted culture at 37°C / 48h, with the best colony count of 30-300.

[0088] 7.2 Determination of bile salt tolerance of Lactobacillus brevis HB-01: Activate the strain preservation glycerol tube, wash once with sterile physiological saline after three activations (one MRS plate, two MRS liquid), and resuspend to 1 / 3 of the original volume with sterile water; then inoculate in 8ml MRS medium with different bile salt concentrations (0.1%, 0.2%, 0.3%) at 1% (v / v), and culture at 37°C / 100rpm. Samples were taken at 0, 2, 4, 6, and 8h respectively and counted by dilution coating plate method, and counted after inverted culture at 37°C / 48h, with the best colony count of 30-300.

[0089] The experimental results are as follows Fig.15 , Fig.16 As shown in the figure, it can be seen that Lactobacillus brevis HB-01 has acid and bile salt resistance.

[0090] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A Lactobacillus brevis ( Lactobacillus brevis ) strain HB-01, characterized in that The Lactobacillus brevis strain HB-01 was deposited in the China Center for Type Culture Collection on May 20, 2022, with the deposit number being CCTCC NO: M2022686.

2. Use of the Lactobacillus brevis strain HB-01 according to claim 1 in the preparation of short-chain fatty acids or γ-aminobutyric acid; the short-chain fatty acid is at least one of acetic acid, propionic acid or butyric acid.

3. Use of the Lactobacillus brevis strain HB-01 according to claim 1 in in vitro digestion of oligosaccharides; the oligosaccharides are at least one of raffinose or stachyose.

4. A method for preparing a fermentation broth containing short-chain fatty acids or γ-aminobutyric acid using the Lactobacillus brevis strain HB-01 according to claim 1, characterized in that: The Lactobacillus brevis strain HB-01 is activated and inoculated into a short-chain fatty acid culture medium or a γ-aminobutyric acid culture medium, and cultured and fermented to obtain the fermentation liquid; the short-chain fatty acid is at least one of acetic acid, propionic acid or butyric acid.

5. The method according to claim 4, characterized in that: The short-chain fatty acid culture medium comprises the following components in percentage by mass: 0.1% Tween-80, 3.0% glucose, 0.5% sodium acetate trihydrate, 0.2% triammonium citrate, 0.2% dipotassium hydrogen phosphate heptahydrate, 1% peptone, 0.5% beef extract powder, 0.4% yeast powder, 0.02% magnesium sulfate heptahydrate and 0.005% manganese sulfate tetrahydrate.

6. The method according to claim 4, characterized in that: The γ-aminobutyric acid culture medium comprises the following components in percentage by mass: 1% sodium glutamate, 0.1% Tween-80, 2.0% glucose, 0.5% sodium acetate trihydrate, 0.2% triammonium citrate, 0.2% dipotassium hydrogen phosphate heptahydrate, 1% peptone, 0.5% beef extract powder, 0.4% yeast powder, 0.02% magnesium sulfate heptahydrate and 0.005% manganese sulfate tetrahydrate.